Welcome to NLS Pharmaceutics
We are seeking to design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are seeking to create new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.
Press Room
Interview with Alex Zwyer, CEO of NLS Pharmaceutics Ltd. (NLS) at The London Stock Exchange Studios. You can see more info of NLS Pharmaceutics on the media in our Press Room section
NLS Pharmaceutics Announces New Study Data Confirming Mazindol’s Unique Orexin Pathway Activation for Treating Narcolepsy
NLS Pharmaceutics Announces Patent Issuance in Europe for its Mazindol Controlled-Release Formulation (Mazindol CR)
NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer
NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazindol CR)
Contact us
NLS Pharmaceutics is very interested in hearing from you. Please find general contact information below.
NLS PHARMACEUTICS GROUP
Alter Postplatz 2
CH-6370 Stans NW
Switzerland
T: +41 41 618 80 00
F: +41 41 618 80 09
askus@nls-pharma.com
